Australia-China Bioinnovation Roundtable 2026 -
2026 Australia–China BioInnovation Roundtable
Going Global, Together
An official satellite event of AusBiotech's Australia's Biggest Week in Biotech
Principal partner: WuXi AppTec
China's biotech companies have gone global fast — record out-licensing volumes and direct deals with the world's largest pharmaceutical firms. Australia has the science, the trials and the incentives, but fewer companies that have made the jump.
Each side has something the other wants. That's the conversation.
Our third Roundtable, held on day one of Australia's Biggest Week in Biotech — a few minutes from the convention centre, while the industry is already in town.
The 2025 edition brought together 100+ delegates across Melbourne and Shanghai, with 43,000 joining online. This one stays deliberately small: half a day, capped at 100, built around discussion rather than presentations.
The afternoon
12:30 Registration and light lunch
13:00 Welcome and opening remarks
Alan Cui, Managing Partner, Boson Ventures · Dr Zhou Zhou, Head of Asia-Pacific Sales & Marketing in Testing, WuXi AppTec · with invited guests
13:15 Scene-setter: the Australian ecosystem
Where Australian biotech stands in 2026, and the challenges it faces. Stu Dignam, CEO, Auscelerate.
13:35 The China perspective
The Chinese ecosystem and a first-hand account of how it has developed.
13:55 Panel: Collaboration Beyond Borders / 跨越边境：引领生命健康创新
How each ecosystem's push to go global is reshaping the way it operates, and where the two paths cross. Moderated discussion, then open floor.
14:55 Afternoon tea
15:20 Spotlight and technical clinic
A keynote from Dr Yi Jin, Vice President and Chief Toxicologist at WuXi AppTec, then cross-border development in practice — including how the R&D tax incentive works when you engage an offshore partner, answered by an Australian tax specialist and a company that has done it.
16:00 Investor panel
The capital view from both markets.
16:50 Roundtable: capital, partnering and going global
Facilitated, no stage. What makes a cross-border partnership work, and what makes one fail.
17:20 Closing remarks
17:30–18:30 Networking drinks
Further speakers announced shortly. Programme subject to minor change.
Who's in the room
Biotech founders and heads of development, from pre-clinical through Phase II. Translational research leaders and commercialisation offices. R&D and partnering teams from Australian pharma. Life sciences investors and cross-border funds. Chinese biotech and pharma delegates attending Australia's Biggest Week in Biotech. R&D tax and IP advisers, CROs and trial networks.
AusBiotech's Australia's Biggest Week in Biotech brings together the biotechnology and life sciences community for a week of sector events, collaboration and connection on the Gold Coast from 19–23 October 2026. The 2026 Australia–China BioInnovation Roundtable is proud to be an official satellite event partner.
2026 澳中生物创新圆桌会议
携手出海 Going Global, Together
AusBiotech「澳大利亚生物科技盛会周」官方活动
首席合作伙伴：药明康德 WuXi AppTec
中国生物医药企业的出海速度惊人——license-out 交易量屡创新高，一批企业已与全球最大的制药公司直接达成合作。澳大利亚拥有扎实的科研、成熟的临床试验环境和优厚的研发激励制度，但真正跨出这一步的企业却不多。
双方各有对方所需。这正是我们要谈的。
这是我们的第三届圆桌会议，安排在「澳大利亚生物科技盛会周」首日举行，距离会展中心仅数分钟路程——行业人士本就齐聚于此。
2025 年那一届在墨尔本与上海两地汇聚了 100 多位与会代表，线上观看人次超过 43,000。本届我们有意控制规模：半天时间，限 100 人，重讨论而非演讲。
当天流程
12:30 签到与简餐
13:00 欢迎致辞与开幕环节
Alan Cui，Boson Ventures 管理合伙人 · 周舟博士，药明康德测试事业部亚太区销售与市场负责人 · 及受邀嘉宾
13:15 开场综述：澳大利亚生态
澳大利亚生物医药产业在 2026 年所处的位置，以及它面对的挑战。Stu Dignam，Auscelerate 首席执行官。
13:35 中国视角
中国生态的发展历程与亲历者的第一手观察。
13:55 圆桌论坛：跨越边境——引领生命健康创新
两个生态各自的出海进程如何重塑其运作方式，两条路径又在何处交汇。主持人引导讨论后开放自由交流。
14:55 茶歇
15:20 专题分享与技术答疑
药明康德副总裁、首席毒理学家金毅博士主题演讲，随后进入跨境研发支持的实操环节——包括与海外合作伙伴合作时研发税收激励如何适用，由澳大利亚税务专家与已成功申请的企业现场解答。
16:00 投资人论坛
来自两个市场的资本视角。
16:50 圆桌讨论：资本、合作与出海
引导式讨论，不设讲台。一段跨境合作成功的关键是什么，失败又往往败在哪里。
17:20 闭幕致辞
17:30–18:30 社交酒会
更多讲者即将公布，议程可能有小幅调整。
与会人群
处于临床前至二期阶段的生物科技企业创始人与研发负责人。转化研究负责人与成果转化机构。澳大利亚药企的研发与合作团队。生命科学投资人与跨境基金。前来参加「澳大利亚生物科技盛会周」的中国生物医药与制药企业代表。研发税务与知识产权顾问、CRO 与临床试验机构。
AusBiotech 主办的「澳大利亚生物科技盛会周」将于 2026 年 10 月 19 至 23 日在黄金海岸举行，汇聚生物科技与生命科学领域的行业活动、合作与交流。2026 澳中生物创新圆桌会议很荣幸成为其官方卫星活动合作伙伴。